-+ 0.00%
-+ 0.00%
-+ 0.00%

Genprex signs MD Anderson research deal to study Reqorsa lung cancer response biomarkers

PUBT·04/21/2026 11:07:14
Listen to the news
Genprex signs MD Anderson research deal to study Reqorsa lung cancer response biomarkers
  • Genprex on April 21, 2026 signed sponsored research agreement with UT MD Anderson to study biomarkers that could predict response to its Reqorsa gene therapy in lung cancer.
  • Findings have not been presented; work will be used to guide future patient selection for Acclaim-1 and Acclaim-3 clinical trials.
  • Genprex expects biomarker work to help identify patients more likely to benefit from Reqorsa, aiming to improve trial outcomes without changing current trial design disclosures.
  • Update follows earlier Acclaim-1 and Acclaim-3 Phase 1 results already presented internally by Genprex as showing tolerability with early signs of benefit in some patients.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genprex Inc. published the original content used to generate this news brief on April 21, 2026, and is solely responsible for the information contained therein.